Administration of dipeptidyl peptidase inhibitors
AssigneeTakeda Pharmaceutical Company Limited
InventorsRonald J. Christopher, Paul Covington
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.
Claims23
1-96. (canceled)
A method of treating type II diabetes mellitus in a patient in need thereof, the method comprising administering to the patient between 5 mg and 250 mg of Compound I, wherein Compound I has the formula
- or a pharmaceutically acceptable salt thereof, in combination with between 125 mg and 2550 mg of metformin or a pharmaceutically acceptable salt thereof.
A method of treating type II diabetes mellitus in a patient in need thereof, the method comprising administering to the patient between 5 mg and 250 mg of Compound I, wherein Compound I has the formula
- or a pharmaceutically acceptable salt thereof, in combination with between 7.5 mg and 60 mg of pioglitazone or a pharmaceutically acceptable salt thereof.
A method of treating type II diabetes mellitus in a patient in need thereof, the method comprising administering to the patient between 5 mg and 250 mg of Compound I, wherein Compound I has the formula
- or a pharmaceutically acceptable salt thereof, in combination with between 125 mg and 2550 mg of metformin or pharmaceutically acceptable salt thereof, and between 7.5 mg and 60 mg of pioglitazone or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.